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ABSTRACT 
Objective: Management of viral hepatitis in patients with HIV disease is quite challenging and complex. With effective HIV 
treatment, people with HIV/HBV co-infection are living longer. HBV epidemiologic surveys showed an inverse association 
between selenium (Se) level and regional cancer incidence, as well as viral infection. This study assessed effect of selenium as 
adjunct to HAART in management of HIV/HBV co-infection.   
Methods: A randomized open label study with participants allocated into three treatment groups: – HAART-only, Se-only and 
HAART-plus-Se. HIV viral load, HBV viral load, CD4 cell count, and alanine aminotransaminase (ALT), were analyzed at 
baseline and 18th month, analyzed using SPSS 5 v11. Ethical approval was obtained from Institute’s Ethical Review Board. 
RESULTS: Sample size was 149 HIV/HBV patients. Rate of HBV clearance was higher among those on HAART-plus-Se at 18th 
month when compared with rate of clearance among those on HAART-only (p=0.046). CD4 count increment among HAART-
plus-Se group compared with HAART-only group was higher (p=0.133), though not statistically significant. On comparison of 
baseline and 18th month ALT, there was significant decline for HAART-plus-Se (p=0.002) compared with HAART-only group.  
CONCLUSION: Selenium seems to have protective effect on liver cells; may be beneficial as adjunct to HAART in HIV/HBV 
management. 
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RESUME   
Objectif: La gestion de l’hépatite virale chez les patients atteints du VIH est assez difficile et complexe. Avec un traitement efficace contre 
le VIH, les personnes atteintes la co – infection du VIH/VHB vivent plus long. Enquêtes épidémiologiques du VHB ont montrés 
une association inverse entre le niveau du sélénium (Se) et l’incidence du cancer  régionale,  ainsi que l’infection  virale. Cette étude a 
évalué l’effet du sélénium comme complément à HAART dans la gestion de la co – infection du VIH/VHB. 
Méthodes : Une  étude ouverte randomisée avec les participants alloués en trois groupes de traitement  : HAART – seulement, Se- 
seulement et HAART – plus- Se. La charge virale du VIH, la charge virale du VHB, la numération des CD4 et alanine 
aminotransaminas (ALT), ont été analysés au base et au 18ème mois, analysés en utilisant SPSS 5 v11. L’approbation éthique a été 
obtenue au comité d’éthique d’examen de l’institut. 
Résultats  :  Le numéro  de l’échantillon était  149 patients  de VIH/VHB. Le taux de clairance du VHB était plus élevé chez les 
personnes sur HAART-plus-Se au 18ème mois par rapport à la vitesse  de  clairance  parmi  ceux  sur  HAART  – seulement 
(p=0,046). L’incrément de CD4 parmi le groupe HAART – plus- Se comparé  au  groupe  HAART  – seulement  était  plus  élevé 
(p=0,133), quoique pas statistiquement  significative. Sur la comparaison  base et ALT  de 18
ème   
mois,  il  y  a  eu baisse 
significative pour HAART – plus – Se (p=0,002) par rapport au groupe de HAART – seulement. 
CONCLUSION: Le sélénium semble d‘avoir un effet protecteur sur les cellules du foie ; peut être bénéfique comme complément à 
HAART dans la gestion du VIH/HBV. 




About 350 million persons are chronically infected 
with hepatitis B virus (HBV) and are at high risk of 
death from active hepatitis, cirrhosis and primary 
hepatocellular carcinoma [1,2]. The rate of liver-
related death is higher in HIV/HBV co-infected 
persons compared with those who have HIV infection 
alone [3]. With effective HIV treatment, people with 
HIV/HBV co-infection are living longer lives. Slower-
progressing liver disease caused by hepatitis B, such 
as liver cancer and liver failure, are now becoming 
key health concerns.  End-stage liver disease (ESLD) 
from viral hepatitis co-infection is now a leading 
cause of death among people with HIV [4]. The 
available reports show that, it is currently not possible 
to completely cure HBV with treatment, since small 
particles of the virus (cccDNA) inserts itself inside the 
nucleus of liver cells, where the drugs cannot 
penetrate. 
However, drugs can control HBV in order to prevent 
or delay development of liver damage. The reported 
burden of hepatitis B infection may be a tip of the 
iceberg as occult infection is seen more commonly in 
HIV-positive individuals and often go undiagnosed. 
This is especially so in low income countries with 
poor diagnostic infrastructure.  
Clinically the coexistence of the two infections leads 
to an increased risk of hepatic cirrhosis and 
hepatocellular carcinoma if not treated [5]. Early 
identification of the coexistence of the two infections 
and prompt treatment is therefore essential in not 
only reducing the associated mortality but improved 
quality of life.  
While the use of highly active antiretroviral therapy 
(HAART) has been shown to change the natural 
course of HIV and effective treatment available for 
persons with HBV, the management of HIV/HBV co-
infection is quite challenging. This is especially so 
when pharmacologic therapy is used, making it 
difficult to identify the ideal strategy for management 
of the co-infection. Selenium (Se) has been reported to 
play a crucial role in the detoxification of liver 
enzymes, enhancing immune function as well as 
providing antioxidant effect [6]. Yu, et al [7] reported 
that epidemiological surveys demonstrated an inverse 
association between Se level and regional cancer 
incidence, as well as HBV infection. He further 
reported that a four-year animal study showed that 
dietary supplement of Se reduced the HBV infection 
by 77.2% and liver precancerous lesion by 75.8%.[8] 
Qia et al reported beneficial effects of Se, vitamin E, 
and beta-carotene on cancer mortality [9]. It has been 
reported that Se appears to be protective in 
individuals infected with hepatitis virus (B or C), 
against the progression of the condition to liver 
cancer [10]. Rayman, in the review of the evidence 
and mechanism of action of Se in cancer prevention, 
reported evidence associating Se ingestion with 
reduction of DNA damage and oxidative stress [10].  
The data showing an effect of selenoprotein genotype 
on cancer risk implied that selenoproteins were 
indeed implicated. Khan et al [11] recently reported 
that serum Se concentration of hepatitis B and C 
patients is less than serum Se concentration of healthy 
individuals and that, serum Se decline is relative to 
increased severity of disease [12].  
This study was conducted to evaluate the effect of 
selenium as adjunct to HAART in the management of 
patients co-infected with HIV/HBV co-infected 
patients. Selenium was found to be reasonably 
beneficial in addition to HAART in the management 
of this group of patients. 
MATERIALS AND METHODS 
Ethics statement: Ethical approval was obtained on 
application from the Institute’s (NIMR) Ethical 
Review Board.  
Study setting:  The study was conducted at the HIV 
treatment centre, Nigerian Institute of Medical 
Research (NIMR), in Lagos. NIMR is the apex medical 
research institution in Nigeria charged with the 
responsibility to conduct research into disease of 
public health importance in the country. At the 
initiation of the Federal Government of Nigeria 
antiretroviral drug access programme in 2002, it was 
selected as one of the 25 treatment centres primarily 
to provide the research backup for the National HIV 
programme.  Patients were enrolled into the HIV 
treatment programme on referral from the HIV 
Counselling and Testing Centre (HCT), NIMR Lagos 
or transferred from other government HIV treatment 
centres. Presently the centre provides free 
comprehensive HIV care, treatment and support for 
over 19,000 patients. 
Study Design: A randomized open label study with 
participants randomly allocated into three treatment 
groups: HAART only, Selenium only and 
HAART+Selenium. The target population was, HIV-1 
sero-positive adult males and females, confirmed by 
Western Blot or a licensed double ELISA procedure, 
antiretroviral drug naïve, and who were HBsAg 
positive and whose baseline serum ALT (alanine 
transaminase), CD4+ lymphocyte counts have been 
evaluated and viral loads quantified by standard 
method at the Human Virology Lab in NIMR. The 
detection limit for the HIV viral load assay was 400 
RNA copies/mL (standard method) and 316 DNA 
copies/mL for HBV. 
199 
 
Sample size calculations: The sample size calculation 
was based on two-proportion method from Epi-
calculator in Epi Info v6. One hundred and forty-nine 
(149) consenting HIV/HBV patients aged 18 years 
and above were counselled and enrolled for the study 
between 2006 and 2008 (figure 1). Excluded from the 
study were participants who declined consent and/or 
are on previous or ongoing treatment with anti-
retroviral agents. A flow chart of patient progress 
through the study is shown in figure 2.  
Treatment Groups: Group 1 (HIV/HBV only) on 
Truvada [Tenofovir (TDF) 300mg plus Emtricitabine 
(FTC) 200mg] with tablet Nevirapine (NVP) 200mg 
once daily for 14 days, then 12 hourly in the absence 
of severe adverse drug reaction, or Efavirenz (EFV) 
where NVP is not applicable. 
Group 2 (HIV/HBV + Selenium): HAART regimen as 
in Group 1 plus 200 mcg selenium daily.                                  
Group 3 (Selenium only): HAART ineligible patients 
on 200 mcg selenium daily.  
Laboratory tests  
CD4 Lymphocyte cell count:  CD4 counts were 
determined for each patient at baseline and 
subsequently on 3 monthly intervals, using the 
Dynalbead Technique (Dynal A.S. Oslo, Norway). This 
was the adopted technique for CD4 estimation under 
the national ARV programme at that time. The CD4 
was expressed as cells/µl of blood. 
Viral load estimations (HIV-1 RNA and HBV DNA): 
The viral load of each patient was quantified with 
200µl plasma samples using the Amplicor HIV-1 
monitor version 1.5 (Roche Diagnostic Systems, 
Branchburg, NJ, USA) and expressed as RNA 
copies/ml. The non-detectable limit of the standard 
method used in this study was 400 copies/ml. 
Hepatitis B markers determined were HBsAg and 
HBV DNA viral load. HBV DNA was measured 
quantitatively using the COBAS AMPLICOR 
technique by Roche (Germany). The minimum 
detection level of the COBAS AMPLICOR was 316 
DNA copies/ml. Therefore undetected was recorded 
as equal to or less than 316 DNA copies/ml.  
Alanine transaminase (ALT): Commercially available 
ELISA kits (RANDOX) were used to assay for the 
serum ALT.  
Follow up: The patients were monitored for their 
response to antiretroviral therapy, through an initial 
two 3-montly evaluation of all parameters estimated 
at baseline, (except HBV viral load, which was 
repeated only at 18th month) as treatment progressed 
and thereafter 6 monthly. Data Management: Data for 
the study was collected using a case record form 
designed for the study. Obtained data was entered 
and analysed using SPSS 5 v11. Comparisons were 
made between groups using student t-test. Summary 
descriptive statistics was carried out on the 
demographic characteristics; baseline, 18th month 
data, ALT, CD4 count, HBV and HIV viral loads, 
were compared between the treatment groups and p-
value less than 0.5 was taken as significant. 
RESULTS                                                                                                                             
Age and sex distributions, of HIV/HBV population 
showed female (59.9%) preponderance. The 
preponderant age groups were 26-35 (41.5%) and 36-
45 (36.1%) years. Twenty one (21) participants were 
lost to follow up. Seven were confirmed dead within 
the study period, (all the seven were HIV/HBV/TB 
co-infected). Only 121 who completed the study had 
repeated HBV DNA analysis at 18th month.  At 
baseline, 32.9% of all the participants had 
undetectable HBV viral load, and at the end of the 
study 72.2% had undetectable HBV viral load. There 
was a significant decrease in HBV viral load of all 
patients who were on HAART plus Se at 18th month 
when compared with baseline data (p=0.001). All 
participants (100%) who had undetectable HBV viral 
load at baseline, were eligible and initiated HAART, 
remained HBV undetected at the end of the study. 
While only 68% of those who were not on HAART, 
and had undetectable HBV viral load at baseline, 
remained undetectable at 18th month (Table 1). 
The rate of HBV clearance was higher among those on 
HAART+Se, when compared with the HAART-only 
group (p=0.046). The CD4 cell count increment 
among HAART+Se group compared with HAART-
only group was higher (p=0.133), though not 
significant. On comparison of baseline and 18th month 
ALT, there was a significant decline for HAART+Se 
treatment group (p=0.05) compared with HAART-
only group (p=0.257).
 
FIGURE 1: AGE DISTRIBUTION OF STUDY PARTICIPANTS
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TABLE 1: COMPARISONS BETWEEN BASELINE AND 18TH MONTH DATA FOR ALL THE TREATMENT GROUPS 
 
Key: ND HBV= undetectable HBV viral load: ND HIV = undetectable HIV viral load, TG 3 = treatment group 3: TG 2 
= treatment group 2: TG 1= treatment group 1: Statistically significant p value ≤0.05 
 
 
TABLE 2: NOT DETECTED HBV AND HIV VIRAL LOADS FREQUENCIES AFTER 18 MONTHS FOR THE STUDY GROUPS
 
DISCUSSION 
At baseline, 27.3% and 7.3% of the participants on 
HAART only had undetectable HBV and HIV viral 
load respectively, and at the end of the 18th month, 
67.3% and 81.8% had undetectable HBV and HIV 
viral loads respectively.   
There was significant difference between baseline and 
18th month HBV and HIV viral loads for this group. 
The HBV and HIV viral loads significantly reduced 
over the 18-month period as anticipated with use of 
ARVs suitable for HIV/HBV co-infection. ALT 
demonstrated mild changes during the study period 
while CD4 increased, though the difference was not  
 
statistically significant. However, it may indicate 
some recovery of immune system with institution of 
HAART in this group. The HBV and HIV viral loads 
decreased significantly over the duration of study. 
This is somewhat similar to what was seen with the 
HAART-only group; however the CD4 increase was 
comparatively higher, probably indicating the 
antioxidant support provided by the co-
administration of selenium. There was also a 
noticeable improvement on the ALT activity in this 
treatment group. This may indicate that selenium is 
likely to have a protective effect on the hepatic cells 
and probably normalizes the liver enzymes. This 
supports some of the earlier reports on selenium [13] of 
Parameters measured TG 3 (N = 23) Se only TG 2 (N = 42) HAART +Se TG 1 (N =50) HAART only 




Baseline  18th month    P value 
2641            316                0.019 
316-2109260      316-1961980 
 Baseline  18th month    P  value 
303,502        316                0.001 
316-6469800          316-10362 
Baseline  18th month    P value 
86,790           316          0.012 
316-6259400   316-1604300 
HIV VL (RNA copies /ml) 
Median 
Range 
Baseline    18th month  P value 
8773             3066             0.013 
200-304648    200-149550 
Baseline    18th month     P value 
155638        200              0.001 
200-487443      200-76861 
Baseline   18th month   P value 
54,720       200                0.003 
200-2692625   200-26735 
CD4 Count (cell/µl) 
Median 
Range 
Baseline     18th month    P 
value 
389               484                0.435 
218-889       212-942 
Baseline      18th month   P value 
103               344                0.001 
8-616           66-999 
Baseline  18th month   P value 
   143           309                0.01 




Baseline     18th month    P 
value 
27                 22                  0.440 
11-65           12-50 
Baseline      18th month    P 
value 
   34                 21               0.05 
5-327             8-58 
Baseline    18th month   P 
value 
26                22             0.257 
11-208        7-192 
Parameters measured TG 1 (N =50) HAART only TG 2 (N = 42) HAART +Se TG 3 (N = 23) Se only 
% ND HBV at baseline 27.3% 31.6% 28.6% 
% ND HBV at 18th month 67.3% 83.8% 25% 
% ND HIV at baseline 7.3% 5.3% 28.6% 
% ND HIV at 18th month 81.8% 81.6% 14.2% 
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beneficial effect of selenium on symptomatic hepatitis 
C patients with elevated aminotransferases when 
placed on a triple antioxidant therapy comprising 
alpha lipoic acid, selenium and 
‘Silybummarianum’(milk thistle).  All the patients 
were reported to have been spared hepatic 
transplantation, for they had improved laboratory 
indices, and returned to normal working life. [14] 
Schwarz et al described the relationship between 
selenium intake by food and prevention of liver 
necrosis in rats. All the parameters were slightly 
improved over the 18-month period, which could be a 
pointer that sole administration of Se compared to 
ART has limited effect on the HBV and HIV 
replication.    
It was observed that there was a relative stability and 
improvement of HBV viral load but deterioration of 
the HIV viral load among the selenium only group. It 
may be adduced that there is need for intervention 
for every HIV/HBV infected patient. Six patients 
opted out of any intervention measure (Se or 
HAART). This group though, a deviation from the 
original study design was followed up along with 
the intervention groups. It was observed that their 
HBV and HIV viral loads were increased after 18 
months while the CD4 cell counts decreased 
significantly. This observation probably depicts the 
natural history of HIV/HBV co-infection in our 
setting. The changes noticed over the period of 
observation were probably facilitated by the 
HIV/HBV co-infection, though different from 
Shuklaet.et al’s suggestion [15] but was similar to 
what Nelson reported [16]. The marker for hepatic 
function (ALT) showed significant deterioration over 
the study period for those on no intervention. The 
laboratory results appeared to correspond to a 
pattern indicating a progression of both the HIV and 
HBV infections in the participants with no 
established form of intervention and may eventually 
lead to death if not controlled. This observation 
indicates that every case of HIV/HBV irrespective of 
the HIV stage may need treatment as early as 
possible. 
When the slight positive change observed on the Se 
only group was compared to the negative change of 
‘no intervention group’ Se, in the absence of any 
other intervention appeared to be beneficial, since it 
seemed to have slowed down the rate of HBV and 
HIV replication to an extent.  In addition, marked 
increase in CD4 cell count over the intervention 
period seemed to correspond with some 
improvement in the immune system following the 
use of Se. The hepatic function appeared stable in 
this group over the duration of intervention as 
shown by stable liver enzyme activities. This may 
indicate that Se is likely to have a protective effect on 
the hepatic cells and probably normalizes the liver 
enzymes. This supports some of the earlier reports of 
beneficial effect of Se on symptomatic hepatitis C 
patients with elevated aminotransferases when 
placed on a triple antioxidant therapy comprising 
alpha lipoic acid, Se and ‘Silybummarianum’(milk 
thistle) [13]. Schwarz et al described the relationship 
between Se intake by food and prevention of liver 
necrosis in rats [14].      However Se alone may not 
stop HBV replication but may normalize the liver 
enzymes as such the findings probably suggest that 
every HIV/HBV co-infected person should be 
started on antiretroviral therapy irrespective of the 
level of CD4 cell count. Nigerian national guidelines 
for HIV/AIDS treatment and care in adolescents and 
adults (2005) did not recommend treatment for all 
HIV/HBV co-infected individuals. Since co-infection 
with HIV seems to speed up HBV disease 
progression, starting HIV treatment with HAART/Se 
earlier may delay or prevent liver damage from 
HBV. The fact that all (100%) participants on TG 1 & 
2, who had undetectable HBV viral load at baseline, 
still remained undetected at 18th month; while only 
68% of those who were not on HAART remained 
undetected at the end of the study, shows that there 
is need to keep monitoring all HBsAg positive 
patients periodically and probably place them on Se 
if mono-infected and baseline HBV viral load 
undetected.  
CONCLUSION 
Apart from enhancing CD4 cell count, selenium 
seems to have a protective effect on liver cells hence 
a resultant normalization of the liver enzymes in 
HBV infection.  It is therefore concluded that 
selenium appears to have a beneficial effect as 
adjunct to HAART in management of HIV/HBV co-
infection and may help to reduce development of 
liver cancer. 
Recommendations: Selenium should be given as 
adjunct to HAART in management of HIV/HBV co-
infection. 
Limitation of the study: We were unable to assess 
the serum selenium level before and after 
intervention as well as other HBV markers due to 
financial constraints.
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